Can liner system and re-stacker assembly therefor
US-12570512-B2 · Mar 10, 2026 · US
Immunogenic compositions comprising progastrin and uses thereof
US8945544B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8945544-B2 |
| Application number | US-80399810-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 12, 2010 |
| Priority date | Dec 19, 2006 |
| Publication date | Feb 3, 2015 |
| Grant date | Feb 3, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention is drawn to immunotherapeutic methods to treat tumors/cancers that produce progastrin ectopically or are dependent on progastrin for their growth. Disclosed herein are immunogenic compositions comprising agents that target progastrin, agents that target the progastrin receptor, annexin II, or both. Such a composition may be administered in combination with chemotherapy or to an individual who had been previously subjected to chemotherapy or radiation therapy. The cancers that may be treated using such a composition may include but are not limited to colon cancer, breast cancer, lung cancer or pancreatic cancer.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating colorectal cancer in a human comprising: administering to a human subject suffering from colorectal cancer a composition comprising a pharmaceutically effective amount of an antibody that specifically binds human progastrin, wherein the antibody blocks binding of human progastrin to an Annexin II receptor, wherein the antibody inhibits the growth-inducing activity of progastrin in the cell, and wherein the antibody is monoclonal or polyc…
Assignees
Inventors
Classifications
Operations & Transport · mapped topic
Operations & Transport · mapped topic
Human Necessities · mapped topic
- B67B3/0645Primary
Operations & Transport · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8945544B2 cover?
- The present invention is drawn to immunotherapeutic methods to treat tumors/cancers that produce progastrin ectopically or are dependent on progastrin for their growth. Disclosed herein are immunogenic compositions comprising agents that target progastrin, agents that target the progastrin receptor, annexin II, or both. Such a composition may be administered in combination with chemotherapy or …
- Who is the assignee on this patent?
- Singh Pomila, Singh Gurpreet, Univ Texas
- What technology area does this patent fall under?
- Primary CPC classification B67B3/0645. Mapped technology areas include Operations & Transport.
- When was this patent published?
- Publication date Tue Feb 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).